Patent details
300855
Product Name:
(2'R)-2'-desoxy-2'-fluor-2'-C-methyluridine-5'-trifosfaat
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
Ok
Cancel
You have not selected any documents
Ok
Basic Information
Publication number:
300855
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2604620
Status:
Refused Art. 10 of the EC Regulations
Application number:
300855
Procedural language:
Dutch
First Applicant Residence Country:
United States of America (US)
Marketing Authorization
Marketing Authorization Number:
EU/1/13/894 (001-002)
Marketing Authorization Type:
EEA
Marketing Authorization Date:
17/01/2014
Marketing Authorization Country:
European Union (EU)
Dates
Filing date:
21/12/2016
First Marketing Authorization date:
17/01/2014
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
27/12/2016
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
20/08/2019
Applicant/holder
From:
27/12/2016
Name:
Gilead Pharmasset LLC
Address:
c/o Gilead Sciences, Inc. 333 Lakeside Drive, FOSTER CITY, CA 94404, United States of America (US)
Agent
Name:
ir. H.A. Witmans c.s.
From:
27/12/2016
Address:
V.O.
Postbus 87930, 2508 DH, Den Haag, Netherlands (NL)
To:
Publication
Bulletin
1
Bulletin Heading:
VRV
Journal edition number:
34/19
Publication date:
21/08/2019
Description:
Lapse or annulment
2
Bulletin Heading:
SPC
Journal edition number:
52/16
Publication date:
28/12/2016
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date
Document type
Document Description
Number of pages
File Type
20/08/2019
Outgoing Correspondence
Decision refusal
2
PDF
/5/0/4/8/1/0800118405/docs/300855_1_outgoingcorrespondence20190821020824434.pdf
29/11/2017
Examination
Internal New
2
PDF
/5/0/4/8/1/0800118405/docs/300855_6_examination20180215151746233.pdf
20/11/2017
Incoming Correspondence Paper
Response applicant or agent
2
PDF
/5/0/4/8/1/0800118405/docs/300855_4_incomingcorrespondencepaper20171122102529780.pdf
31/08/2017
Outgoing Correspondence
Outgoing Letter
2
PDF
/5/0/4/8/1/0800118405/docs/300855_5_outgoingcorrespondence20170904030541590.pdf
28/12/2016
Outgoing Correspondence
Confirmation receipt request
1
PDF
/5/0/4/8/1/0800118405/docs/300855_3_106851l174.pdf
22/12/2016
SPC Documents
Marketing Authorization SPC
3
PDF
/5/0/4/8/1/0800118405/docs/300855_0_supplprotectioncertificate20161227085404475.pdf
22/12/2016
Application Form
First filed application form
3
PDF
/5/0/4/8/1/0800118405/docs/300855_2_applicationform20161227085404289.pdf
22/12/2016
SPC Documents
Summary of the characteristics of the product
42
PDF
/5/0/4/8/1/0800118405/docs/300855_7_supplprotectioncertificate20161227085404563.pdf